Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267020 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Neoplasm, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT00267020: Completed Phase 2 study of Pancreatic Neoplasm, sponsored by Eli Lilly and Company.
NCT00267020 is a Phase 2 study of Pancreatic Neoplasm that has completed, run by Eli Lilly and Company. The registered enrollment target is 130 participants, below the 647-participant average among 10 other Pancreatic Neoplasm trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00267020, a Phase 2 study of Pancreatic Neoplasm, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.
Primary Outcome
OS was the duration from randomization to death. OS was censored at the last contact for participants who were alive, at the cut-off date.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG enzastaurin
Study Locations (1)
Texas
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
What the finished NCT00267020 record still lists
NCT00267020 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 10 other Pancreatic Neoplasm trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Pancreatic Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.
NCT00267020 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00267020 about?
NCT00267020 is a clinical study titled "Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer". The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.
What is the current status of trial NCT00267020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2005-12. Estimated completion is 2008-05.
What conditions does trial NCT00267020 study?
This clinical trial studies the following conditions: Pancreatic Neoplasm.
What interventions are being tested in trial NCT00267020?
The interventions under investigation include: gemcitabine (DRUG), enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00267020?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00267020 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00267020's enrollment target sits among peer trials
130 5th of 10 higher than 6 of 10 other Pancreatic Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
RECRUITING · Phase 2
-
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
COMPLETED · Phase 2
-
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
RECRUITING · Phase 3
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
RECRUITING · Early Phase 1
-
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
RECRUITING · Phase 1
-
Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia